Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UT-15 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| UT-15 | DRUG | - |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of moderate to severe precapillary pulmonary hypertension (New York Heart Association class III/IV) unresponsive to attempted use of chronic oral vasodilators for at least 1 month Cardiac catheterization at baseline: Pulmonary artery ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
UT-15 is an investigational small molecule being developed for the treatment of pulmonary hypertension, a condition of high blood pressure in the arteries of the lungs. It is being studied in patients with primary pulmonary hypertension, a specific form of the disease. The drug is currently in Phase 3 clinical development.
UT-15 is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the safety and efficacy of UT-15 for the treatment of pulmonary hypertension.
UT-15 is in Phase 3 clinical development for the treatment of pulmonary hypertension. It has completed one Phase 3 clinical trial, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities. Further development and regulatory review are required before it can be marketed.
UT-15 has been studied in a completed Phase 3 clinical trial with the identifier NCT00004497, titled 'Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension.' The trial was conducted in the United States and enrolled patients aged 8 years and older with pulmonary hypertension.
UT-15 is the drug name used in clinical development by United Therapeutics Corporation. No alternative names for UT-15 have been reported in the available clinical trial information. The drug is being studied under this name in the context of its Phase 3 trial for pulmonary hypertension.